Laura Tasca is a Senior Drug Development Associate at Kither Biotech, where she supports the development of KIT2014, a dual PDE3/4 inhibitor in Phase 1 trials for cystic fibrosis. She works across Chemistry, Manufacturing & Controls (CMC), preclinical strategy, and clinical trial design, with a focus on accelerating proof-of-concept and regulatory progress. Her responsibilities include indication expansion strategies, using preclinical data and competitive intelligence to explore new therapeutic areas. She also contributes to preparing regulatory submissions, such as Orphan Drug Designation and Clinical Trial Applications, and coordinating with regulatory authorities and patient associations.
Laura holds a Master’s degree in Industrial Biotechnology and a Bachelor’s degree in Biotechnology from the University of Turin. Her research on therapeutic peptides for cystic fibrosis has been published in The Journal of Biological Chemistry. She has also completed advanced training in regulatory affairs, drug development, and clinical trial management through programs at Duke University, UC San Diego, and Novartis, and has experience in market analysis, business development, and scientific communication.